- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements:
· | Registration Statement (Form S-8 No. 333-217002) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan, |
· | Registration Statement (Form S-8 No. 333-208579) pertaining to the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan |
· | Registration Statement (Form S-8 No. 333-226824) pertaining to Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan, and |
· | Registration Statement (Form S-3 No. 333-214859) of Axsome Therapeutics, Inc. and in the related Prospectus; |
of our report dated March 14, 2019, with respect to the consolidated financial statements of Axsome Therapeutics, Inc. included in this Annual Report (Form 10-K) of Axsome Therapeutics, Inc. for the year ended December 31, 2018.
|
|
| /s/ Ernst & Young LLP |
|
|
New York, NY |
|
March 14, 2019 |
|